Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS016 versus Humira in active ankylosing spondylitis
ChiCTR1900022520Phase 3Completed
- Sponsor
- Peking Union Medical College Hospital
- Start
- Aug 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of anjianning in ankylosing spondylitis (AS) (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: Percentage of subjects who achieved ASAS 20 response at 24 weeks. Started Aug 2016; status: completed.
02
Drugs
anjianning
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on ChiCTR1900022520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900022520.